Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

JNJ - Johnson & Johnson Последние новости | Finranks

Home

/

JNJ

J

Johnson & Johnson (JNJ)

NYQ – Цена в реальном времени. Валюта: USD

260.65

+0.85 (0.33%)

Рынок открыт: Aug 12, 2026, 11:29 AM EDT

260.00

+0.20 (0.08%)

Предыдущая сессия: Aug 11, 2026, 7:59 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Johnson & Johnson Nearing 52-Week High: Buy, Sell or Hold?

Johnson & Johnson Nearing 52-Week High: Buy, Sell or Hold?

At $261.81, Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a hold.

J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?

J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?

J&J's growth, new drug launches and pipeline strength support the stock, despite patent, MedTech and legal headwinds.

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14th, 2026. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will.

3 Beaten-Down Healthcare Stocks to Buy in August

3 Beaten-Down Healthcare Stocks to Buy in August

Year to date, the healthcare sector finds itself in the middle of the S&P 500's pack.

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.

Few companies have a longer track record of uninterrupted dividend growth. This streak is likely to be prolonged well into the foreseeable future.

Why PG, JNJ, and KO Could Surprise Investors Next Year

Why PG, JNJ, and KO Could Surprise Investors Next Year

Defensive blue chips rarely dominate headlines, but heading into 2027, three of the market's most reliable dividend payers stand out as durable compounders.

Johnson & Johnson (JNJ) Could Be a Great Choice

Johnson & Johnson (JNJ) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

Видео

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Пресс-релизы

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9th, 2026. Management will participate in a Fireside Chat at 11:00 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available ap.

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine following a distinguished career and over 21-year tenure at Johnson & Johnson. Under her leadership, the Company's Innovative Medicine business grew to more than $60 billion in annual revenue and strengthened its position as one of the most respected and successful pharmaceutical busin.